Viatris Inc. (VTRS) Free Cash Flow Yield: 9.46%
Is Viatris Inc.’s free cash flow yield high or low?
Viatris Inc.'s free cash flow yield of 9.46% is 41% below its 5-year average of 16.03%, near the low end of its 5-year range (8.37%–29.41%).
As of Sunday, June 21, 2026. 24.10% below its 12-month average of 12.46%.
VTRS Free Cash Flow Yield Chart
VTRS Average Free Cash Flow Yield Chart
VTRS Current vs Average Free Cash Flow Yield Chart
VTRS Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
9.46%
FREE CASH FLOW YIELD AVG TTM
12.46%
FREE CASH FLOW YIELD AVG 3Y
14.77%
FREE CASH FLOW YIELD AVG 5Y
15.99%
FREE CASH FLOW YIELD AVG 10Y
14.35%
FREE CASH FLOW YIELD AVG 15Y
N/A
FREE CASH FLOW YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
-24.10%
CURRENT VS 3Y AVG
-35.93%
CURRENT VS 5Y AVG
-40.84%
CURRENT VS 10Y AVG
-34.09%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
VTRS Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $17.90B | 9.46% | 12.46% | 14.77% | 15.99% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 10.66% | 8.74% | 6.11% | 5.51% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 5.82% | 6.28% | 5.68% | 7.87% |
| Incyte Corporation (INCY)vs › | $19.62B | 7.14% | 5.79% | 4.27% | 4.07% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 6.53% | 5.80% | 5.23% | 7.17% |
| DaVita Inc. (DVA)vs › | $13.34B | 10.43% | 12.79% | 12.07% | 12.08% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 5.54% | 4.68% | 4.57% | 4.51% |
| Solventum Corporation (SOLV)vs › | $13.06B | N/A | 2.46% | 7.43% | 7.43% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 5.26% | 5.43% | 3.80% | 3.06% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 4.01% | 5.22% | 5.78% | 5.82% |
Yield Comparison
FCF Yield
9.46%
Earnings Yield
N/A
Dividend Yield
3.12%
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
Viatris Inc. Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Free Cash Flow Yield FAQ
- What is the free cash flow yield for Viatris Inc. (VTRS)?
- The free cash flow yield for VTRS stock is 9.46%.
- Is Viatris Inc.'s free cash flow yield high or low?
- Viatris Inc.'s free cash flow yield of 9.46% is 41% below its 5-year average of 16.03%, near the low end of its 5-year range (8.37%–29.41%).
- What is the TTM average free cash flow yield for Viatris Inc. (VTRS)?
- The TTM average free cash flow yield for VTRS stock is 12.46%.
- What is the 3Y average free cash flow yield for Viatris Inc. (VTRS)?
- The 3Y average free cash flow yield for VTRS stock is 14.77%.
- What is the 5Y average free cash flow yield for Viatris Inc. (VTRS)?
- The 5Y average free cash flow yield for VTRS stock is 15.99%.
- What is the 10Y average free cash flow yield for Viatris Inc. (VTRS)?
- The 10Y average free cash flow yield for VTRS stock is 14.35%.
Viatris Inc. Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-18 | 9.46% |
| 2026-06-17 | 9.25% |
| 2026-06-16 | 9.07% |
| 2026-06-15 | 8.91% |
| 2026-06-12 | 8.83% |
| 2026-06-11 | 8.92% |
| 2026-06-10 | 9.23% |
| 2026-06-09 | 8.98% |
| 2026-06-08 | 9.13% |
| 2026-06-05 | 9.16% |
| 2026-06-04 | 9.15% |
| 2026-06-03 | 9.35% |
| 2026-06-02 | 9.27% |
| 2026-06-01 | 9.20% |
| 2026-05-29 | 8.94% |
| 2026-05-28 | 9.03% |
| 2026-05-27 | 8.93% |
| 2026-05-26 | 8.94% |
| 2026-05-22 | 8.73% |
| 2026-05-21 | 8.83% |
| 2026-05-20 | 8.77% |
| 2026-05-19 | 8.99% |
| 2026-05-18 | 8.82% |
| 2026-05-15 | 8.83% |
| 2026-05-14 | 8.42% |
| 2026-05-13 | 8.38% |
| 2026-05-12 | 8.47% |
| 2026-05-11 | 8.60% |
| 2026-05-08 | 8.47% |
| 2026-05-07 | 8.37% |
| 2026-05-06 | 9.90% |
| 2026-05-05 | 10.17% |
| 2026-05-04 | 10.40% |
| 2026-05-01 | 10.50% |
| 2026-04-30 | 10.57% |
| 2026-04-29 | 10.55% |
| 2026-04-28 | 10.66% |
| 2026-04-27 | 10.66% |
| 2026-04-24 | 10.82% |
| 2026-04-23 | 10.71% |
| 2026-04-22 | 10.88% |
| 2026-04-21 | 10.72% |
| 2026-04-20 | 10.62% |
| 2026-04-17 | 10.76% |
| 2026-04-16 | 11.27% |
| 2026-04-15 | 11.39% |
| 2026-04-14 | 11.35% |
| 2026-04-13 | 11.42% |
| 2026-04-10 | 11.72% |
| 2026-04-09 | 11.60% |
| 2026-04-08 | 11.64% |
| 2026-04-07 | 12.00% |
| 2026-04-06 | 11.78% |
| 2026-04-02 | 11.75% |
| 2026-04-01 | 11.59% |
| 2026-03-31 | 11.70% |
| 2026-03-30 | 12.18% |
| 2026-03-27 | 12.11% |
| 2026-03-26 | 11.81% |
| 2026-03-25 | 11.70% |
| 2026-03-24 | 11.82% |
| 2026-03-23 | 11.89% |
| 2026-03-20 | 11.96% |
| 2026-03-19 | 11.70% |
| 2026-03-18 | 11.49% |
| 2026-03-17 | 11.44% |
| 2026-03-16 | 11.70% |
| 2026-03-13 | 11.70% |
| 2026-03-12 | 11.44% |
| 2026-03-11 | 11.30% |
| 2026-03-10 | 11.22% |
| 2026-03-09 | 11.11% |
| 2026-03-06 | 11.15% |
| 2026-03-05 | 10.87% |
| 2026-03-04 | 10.74% |
| 2026-03-03 | 10.60% |
| 2026-03-02 | 10.06% |
| 2026-02-27 | 10.58% |
| 2026-02-26 | 10.35% |
| 2026-02-25 | 8.54% |
| 2026-02-24 | 8.55% |
| 2026-02-23 | 8.61% |
| 2026-02-20 | 8.63% |
| 2026-02-19 | 8.59% |
| 2026-02-18 | 8.55% |
| 2026-02-17 | 8.73% |
| 2026-02-13 | 8.71% |
| 2026-02-12 | 8.70% |
| 2026-02-11 | 8.51% |
| 2026-02-10 | 8.61% |
| 2026-02-09 | 8.83% |
| 2026-02-06 | 9.42% |
| 2026-02-05 | 9.58% |
| 2026-02-04 | 9.56% |
| 2026-02-03 | 10.04% |
| 2026-02-02 | 10.04% |
| 2026-01-30 | 10.49% |
| 2026-01-29 | 10.50% |
| 2026-01-28 | 10.58% |
| 2026-01-27 | 10.47% |
| 2026-01-26 | 10.43% |
| 2026-01-23 | 10.40% |
| 2026-01-22 | 10.37% |
| 2026-01-21 | 10.53% |
| 2026-01-20 | 10.85% |
| 2026-01-16 | 10.67% |
| 2026-01-15 | 10.70% |
| 2026-01-14 | 10.44% |
| 2026-01-13 | 10.27% |
| 2026-01-12 | 10.83% |
| 2026-01-09 | 10.76% |
| 2026-01-08 | 10.89% |
| 2026-01-07 | 11.03% |
| 2026-01-06 | 11.07% |
| 2026-01-05 | 11.10% |
| 2026-01-02 | 11.03% |
| 2025-12-31 | 11.03% |
| 2025-12-30 | 10.95% |
| 2025-12-29 | 11.10% |
| 2025-12-26 | 11.15% |
| 2025-12-24 | 11.22% |
| 2025-12-23 | 11.43% |
| 2025-12-22 | 11.43% |
| 2025-12-19 | 11.51% |
| 2025-12-18 | 11.49% |
| 2025-12-17 | 11.74% |
| 2025-12-16 | 11.98% |
| 2025-12-15 | 11.78% |
| 2025-12-12 | 11.79% |
| 2025-12-11 | 11.85% |
| 2025-12-10 | 11.83% |
| 2025-12-09 | 12.27% |
| 2025-12-08 | 12.38% |
| 2025-12-05 | 12.56% |
| 2025-12-04 | 12.76% |
| 2025-12-03 | 12.67% |
| 2025-12-02 | 12.82% |
| 2025-12-01 | 12.84% |
| 2025-11-28 | 12.85% |
| 2025-11-26 | 12.90% |
| 2025-11-25 | 13.00% |
| 2025-11-24 | 12.99% |
| 2025-11-21 | 13.12% |
| 2025-11-20 | 13.48% |
| 2025-11-19 | 13.12% |
| 2025-11-18 | 12.82% |
| 2025-11-17 | 12.89% |
| 2025-11-14 | 12.80% |
| 2025-11-13 | 12.58% |
| 2025-11-12 | 12.47% |
| 2025-11-11 | 12.25% |
| 2025-11-10 | 13.50% |
| 2025-11-07 | 13.57% |
| 2025-11-06 | 13.59% |
| 2025-11-05 | 13.44% |
| 2025-11-04 | 13.77% |
| 2025-11-03 | 13.72% |
| 2025-10-31 | 13.95% |
| 2025-10-30 | 13.95% |
| 2025-10-29 | 14.06% |
| 2025-10-28 | 14.04% |
| 2025-10-27 | 13.87% |
| 2025-10-24 | 13.97% |
| 2025-10-23 | 14.03% |
| 2025-10-22 | 13.89% |
| 2025-10-21 | 13.91% |
| 2025-10-20 | 14.03% |
| 2025-10-17 | 14.20% |
| 2025-10-16 | 14.31% |
| 2025-10-15 | 14.47% |
| 2025-10-14 | 14.56% |
| 2025-10-13 | 14.66% |
| 2025-10-10 | 14.84% |
| 2025-10-09 | 14.47% |
| 2025-10-08 | 14.49% |
| 2025-10-07 | 14.25% |
| 2025-10-06 | 14.27% |
| 2025-10-03 | 14.18% |
| 2025-10-02 | 14.29% |
| 2025-10-01 | 14.33% |
| 2025-09-30 | 14.60% |
| 2025-09-29 | 15.02% |
| 2025-09-26 | 15.17% |
| 2025-09-25 | 15.22% |
| 2025-09-24 | 14.88% |
| 2025-09-23 | 15.06% |
| 2025-09-22 | 14.77% |
| 2025-09-19 | 14.60% |
| 2025-09-18 | 14.66% |
| 2025-09-17 | 15.02% |
| 2025-09-16 | 15.11% |
| 2025-09-15 | 15.06% |
| 2025-09-12 | 14.51% |
| 2025-09-11 | 14.20% |
| 2025-09-10 | 14.10% |
| 2025-09-09 | 13.83% |
| 2025-09-08 | 13.79% |
| 2025-09-05 | 13.76% |
| 2025-09-04 | 13.99% |
| 2025-09-03 | 13.70% |
| 2025-09-02 | 13.68% |
| 2025-08-29 | 13.70% |
| 2025-08-28 | 13.89% |
| 2025-08-27 | 13.87% |
| 2025-08-26 | 13.89% |
| 2025-08-25 | 13.70% |
| 2025-08-22 | 13.57% |
| 2025-08-21 | 13.51% |
| 2025-08-20 | 13.57% |
| 2025-08-19 | 13.53% |
| 2025-08-18 | 13.59% |
| 2025-08-15 | 13.62% |
| 2025-08-14 | 13.51% |
| 2025-08-13 | 13.89% |
| 2025-08-12 | 14.29% |
| 2025-08-11 | 14.66% |
| 2025-08-08 | 14.90% |
| 2025-08-07 | 15.38% |
| 2025-08-06 | 17.73% |
| 2025-08-05 | 17.27% |
| 2025-08-04 | 17.36% |
| 2025-08-01 | 17.61% |
| 2025-07-31 | 17.76% |
| 2025-07-30 | 17.24% |
| 2025-07-29 | 16.89% |
| 2025-07-28 | 16.75% |
| 2025-07-25 | 16.47% |
| 2025-07-24 | 16.58% |
| 2025-07-23 | 16.56% |
| 2025-07-22 | 16.78% |
| 2025-07-21 | 17.42% |
| 2025-07-18 | 17.48% |
| 2025-07-17 | 16.72% |
| 2025-07-16 | 17.09% |
| 2025-07-15 | 17.36% |
| 2025-07-14 | 16.98% |
| 2025-07-11 | 17.01% |
| 2025-07-10 | 16.78% |
| 2025-07-09 | 16.81% |
| 2025-07-08 | 16.75% |
| 2025-07-07 | 16.86% |
| 2025-07-03 | 16.64% |
| 2025-07-02 | 16.61% |
| 2025-07-01 | 16.89% |
| 2025-06-30 | 17.36% |
| 2025-06-27 | 17.21% |
| 2025-06-26 | 17.01% |
| 2025-06-25 | 17.45% |
| 2025-06-24 | 17.33% |
| 2025-06-23 | 17.54% |
| 2025-06-20 | 17.48% |
| 2025-06-18 | 17.70% |
| 2025-06-17 | 17.70% |
| 2025-06-16 | 17.24% |
| 2025-06-13 | 17.39% |
| 2025-06-12 | 17.06% |
| 2025-06-11 | 17.27% |
| 2025-06-10 | 17.15% |
| 2025-06-09 | 17.61% |
| 2025-06-06 | 17.83% |
Showing the most recent 260 of 3,011 data points. The chart above shows the full history.
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith